All In Biotech

Drug Trial Radar · NCT07624175

Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso

Immunogenicity and Tolerability of Typhoid Conjugate Vaccine (TCV) 5-6 Years After Routine Vaccines Administered With or Without TCV Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

147

Actual

Start

Aug 17, 2024

Primary completion

Oct 26, 2024

Study completion Oct 26, 2024

Sponsor

Lead sponsor
Kathleen NeuzilAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Groupe de Recherche Action en Sante
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 7 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later. Children previously enrolled in a Phase 2 randomized clinical trial of Vi-tetanus toxoid conjugate vaccine (Vi-TT) were re-enrolled at 6-7 years of age. Participants who previously received Vi-TT received a booster dose of Vi-CRM, while control participants received their first TCV dose. Anti-Vi IgG antibody responses were measured at baseline and 28 days post-vaccination. Safety was assessed through solicited and unsolicited adverse events. This study provides data on durability of TCV immunity and the potential role of booster dosing in endemic settings.

Conditions

  • Typhoid

Interventions

  • Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IMBiological

    Typhoid conjugate vaccine: Vi capsular polysaccharide conjugated to CRM197 carrier protein, administered as 0.5mL intramuscularly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anti-Vi IgG Antibody Response (Immunogenicity)Time frame: Baseline (Day 0) and Day 28 post-vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Schiphra Protestant Hospital

    Ouagadougou, Burkina Faso

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.